Influence of fluoroquinolone purchasing patterns on antimicrobial expenditures and Pseudomonas aeruginosa susceptibility

American Journal of Health-System Pharmacy

Volumn 56, Issue 21, 1999, Pages 2217-2223

  Rifenburg, Robert P ^a   Paladino, Joseph A ^b,c   Bhavnani, Sujata M ^b   Den Haese, Diane ^d   Schentag, Jerome J ^b  

^a MILLARD FILLMORE HOSPITAL   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c Millard Fillmore Suburban Hospital   (United States)

^d SUNY ^*

Author keywords

Anti infective agents; Ciprofloxacin; Costs; Drug comparisons; Drug use; Hospitals; Ofloxacin; Quinolones; Resistance

Indexed keywords

ANTIINFECTIVE AGENT; CIPROFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; DRUG COST; HOSPITAL PURCHASING; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

EID: 0033230912     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/56.21.2217     Document Type: Article

References (25)

1. Phillips I, King A, Shannon K. In vitro properties of the quinolones. In: Andriole VT, ed. The quinolones. London, England: Academic Press; 1988:83-117.
2. Wolfson JS, Hooper DC. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother. 1985; 28:581-6.
3. Eliopoulos GM, Eliopoulos CT. Quinolone antibacterial agents: activity in vitro. In: Wolfson JS, Hooper DC, eds. Quinolone antimicrobial agents. Washington, DC: American Society for Microbiology; 1989:35-70.
4. Stahlmann R, Lode H. Safety overview: toxicity, adverse effects, and drug interactions. In: Andriole VT, ed. The quinolones. London, England: Academic Press; 1988:201-33.
5. Norris S, Mandell GL. The quinolones: history and overview. In: Andriole VT, ed. The quinolones. London, England: Academic Press; 1988:1-22.
6. Karabalut N, Drusano GL. Pharmacokinetics of the quinolone antimicrobial agents. In: Hooper DC, Wolfson JS, eds. Quinolone antimicrobial agents. 2nd ed. Washington, DC: American Society for Microbiology; 1993:195-223.
7. Cardinale V, ed. Drug topics red book. Montvale, NJ: Medical Economics; 1996:185,256.
8. Rifenburg RP, Paladino JA, Hanson SC et al. Benchmark analysis of strategies hospitals use to control antimicrobial expenditures. Am J Health-Syst Pharm. 1996; 53:2054-62.
9. McManus MC. Mechanisms of bacterial resistance to antimicrobial agents. Am J Health-Syst Pharm. 1997; 54:1420-33.
10. Schentag JJ, Paladino JA, Birmingham MC et al. Use of benchmarking techniques to justify the evolution of antibiotic management programs in healthcare systems. J Pharm Technol. 1995; 11:203-10.
11. Kennedy DL, Forbes MB, Baum C et al. Antibiotic use in US hospitals in 1981. Am J Hosp Pharm. 1983; 40:797.
12. Andriole VT. Clinical overview of the newer 4-quinolone antibacterial agents. In: Andriole VT, ed. The quinolones. London, England: Academic Press; 1988:155-200.
13. McCue JD, Gaziano P, Orders D. A randomized controlled trial of ofloxacin 200 mg 4 times daily vs ciprofloxacin 500 mg twice daily in elderly nursing home patients with complicated UTI. Drugs. 1995; 49(suppl 2):368-73.
14. Polubiec A, Jorasz I, Pietrazk J et al. A randomized study comparing low dose ciprofloxacin and ofloxacin in the treatment of lower respiratory tract infections. Infection. 1994; 22 (1):62-4.
15. Stein GE. Fluoroquinolone resistance patterns after formulary addition of ofloxacin. Drugs. 1995; 49(suppl 2):188-9.
16. Chow JW, Fine MJ, Shales DM et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med. 1991; 115:585-90.
17. Goldman DA, Weinstein RA, Wenzel RP et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. JAMA. 1996; 275: 234-40.
18. Schentag JJ. Understanding and managing resistance in institutional settings. Am J Health-Syst Pharm. 1995; 52(suppl 2): S9-14.
19. Thomas JK, Forrest A, Bhavnani SM et al. Pharmacodynamic evaluation of factors contributing to the selection of bacterial resistance in acutely ill patients. Antimicrob Agents Chemother. 1998; 42:521-7.
20. Schentag JJ, Nix DE, Forrest A. Pharmacodynamics of the fluoroquinolones. In: Hooper DC, Wolfson JS, eds. Quinolone antimicrobial agents. 2nd ed. Washington, DC: American Society for Microbiology; 1993:259-71.
21. Schentag JJ, Nix DE, Adelman MH. Mathematical examination of dual individualization principles (I). Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. DICP Ann Pharmacother. 1991; 25:1050-7.
22. Madaras-Kelly KJ, Larrson AJ, Rotschafer JC. A pharmacodynamic evaluation of ciprofloxacin and ofloxacin against two strains of Pseudomonas aeruginosa. J Antimicrob Chemother. 1996; 37:703-10.
23. Schentag JJ, Paladino JA. Pharmacodynamic rationale for selecting the fluoroquinolones. Infect Dis Clin Pract. 1999; 8 (suppl 1): S23-7.
24. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for anti-bacterial dosing of mice and men. Antimicrob Agents Chemother. 1998; 26:1-12.
25. Lamp KC, Gray CD. Ciprofloxacin, ofloxacin, and levofloxacin activity against multiply-resistant Pseudomonas aeruginosa. J Infect Dis Pharmacother. 1998; 3:1-12.